BioStock: Evaxion reaches key milestones during summer

Summer time is generally a rather quiet period for companies based in the Nordics. However, Danish Evaxion Biotech did not stand still this summer, reaching two important milestones. First came promising results with EVX-B1, an AI-designed vaccine against the antibiotic resistant bacteria staphylococcus aureus. Then Evaxion announced entering into a binding agreement with the Dubai-based financial institution Global Growth Holding Limited for financing of up to USD 20 million. BioStock spoke with Evaxion’s CEO Per Norlén to learn more.

Read the interview with Per Norlén at biostock.se:

Evaxion reaches key milestones during summer - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/